B-cell chronic lymphocytic leukemia

Precursor B-cell neoplasm Precursor B-lymphoblastic leukemia/lymphoma Mature (peripheral) B-cell neoplasms B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma... [Pg.1374]

Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000 95 627-632. [Pg.346]

Voss Tet al. Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int J Cancer 2001 91 180-186. [Pg.119]

TGN1412 (CD28-SuperMAb) is a humanized monoclonal antibody that binds and acts as an agonist for the CD28 receptor of the immune system s T cell. It is intended to treat B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis. [Pg.195]

Granziero L, Ghia P, Circosta P et al (2001) Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97 2777-2783... [Pg.225]

Campath (Alemtuzumab) CD52 Humanized IgG B-cell chronic lymphocytic leukemia 2001... [Pg.278]

Indications Treatment of patients with B-cell chronic lymphocytic leukemia who... [Pg.299]

B. Indications and nse Campath is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Determination of the effectiveness of Campath is based on overall response rates. Comparative randomized trials demonstrating increased survival or clinical benefits such as improvement in disease-related symptoms have not yet been conducted. [Pg.299]

E. Therapeutic response The safety and efficacy of Campath were evaluated in an open-label study of 93 patients with B-cell chronic lymphocytic leukemia (B-CLL). A partial response was observed in 31% of patients and a complete response in 2%. The median duration of response was 7 months. [Pg.300]

Treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy... [Pg.469]

Keating M, Coutre S, Rai K et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004 4 220-227. [Pg.227]

Montillo M, Schinkoethe T, Elter T. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cawcer/wvext 2005 23 488-496. [Pg.227]

Farag, SS, Flinn IW, Modali R et al. Fc gamma Rllla and Fc gamma Rlla polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. B/ooii2004 103 1472-1474. [Pg.229]

Campath (Mab) B-cell chronic lymphocytic leukemia rCHO... [Pg.136]

D2. D Arena, G., Dell Olio, M., Musto, P., Cascavilla, N., Perla, G., Savino, L., and Greco, M. M., Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density. Leuk. Lymphoma 42, 649-654 (2001). [Pg.334]

Stratowa C, Loffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, Dohner H, Wilgenbus KK. CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer 2001 91 474-480. [Pg.411]

Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999 94(7) 2217-24. [Pg.239]

Cavalli-Bjorkman N, Osby E, Lundin J, Kalin M, Osterborg A, Gruber A. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B cell chronic lymphocytic leukemia. Med Oncol 2002 19(4) 277-80. [Pg.72]

Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma implications for clinical trials in this patient population. Cancer 2002 94(7) 2033-9. [Pg.1392]

Alemtuzumab (Campath) Anti-CD52 Ab - B-cell chronic lymphocytic leukemia - Preconditioning regimen for bone marrow and renal transplantation -HUS -Acute renal failure - Acute humoral rejection 98,99,101... [Pg.684]

ALL, acute lymphocytic leukemia BL, Burkitt lymphoma B-CLL, B-cell chronic lymphocytic leukemia B-LBL, B-cell lymphoblastic lymphoma cHL, classic Hodgkin s lymphoma DLBCL, diffuse large B-cell lymphoma FL, follicular lymphoma LPHL, lymphocyte-predominant Hodgkin s lymphoma MCL, mantle cell lymphoma MZL, marginal zone B-cell lymphoma. [Pg.2440]

Lin TS, Lucas MS, Byrd JC. Rimximab in B-cell chronic lymphocytic leukemia. Semin Oncol 2003 30 483 92. [Pg.2524]

Byrd JC, Peterson BL, Morrison VL, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with ritux-imab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia Results from Cancer and Leukemia Group B 9712. Blood 2003 101 6-14. [Pg.2524]

Christensen DJ, Chen Y, Oddo J et al (2011) SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma a predictor of aggressive disease and a new treatment target. Blood 118 4150 158... [Pg.303]

Wang, J., Coombes, K. R., Highsmith, W. E., Keating, M. J., Abruzzo, L. V. 2004. Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells A meta-analysis of three microarray studies. Bioinformatics... [Pg.148]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...